C-Terminal Amidated Peptide Free-Acid Impurity QC

Why a one-dalton assignment becomes difficult

For a singly charged small peptide, the acid/amide difference may be visible with adequate resolving power. For a larger peptide carrying several charges, the observed m/z separation is divided by charge. At 4+, the difference is roughly 0.246 m/z. Isotope envelopes can overlap, and a deamidated side chain elsewhere in the sequence can introduce a similar +0.984 Da shift relative to an amide.

The theoretical mass calculation must include every terminal and side-chain modification. Compare monoisotopic with monoisotopic values; average molecular weight copied from a catalog is not an acceptable reference. Review raw charge states rather than only the software's neutral-mass output.

Free-acid material can arise when the wrong resin is used, cleavage occurs from an acid-generating support, amidation chemistry is incomplete, or a precursor is mislabeled. During solid-phase synthesis, an amide-generating resin typically defines the C-terminus from the start. Post-synthetic solution amidation is possible but introduces activation by-products and incomplete conversion risks.

Build a method that resolves identity and amount

LC-HRMS should extract ions for both theoretical structures at the same chromatographic scale. A free-acid impurity may shift retention modestly, but the direction and magnitude are sequence-dependent. Use a shallow gradient around the principal peak and avoid overloading, which can bury a close impurity under the main band.

MS/MS should provide C-terminal fragments supporting the terminal form. Fragmentation behavior differs between peptide amides and free acids, yet sequence coverage can be incomplete. A few N-terminal b ions cannot establish the C-terminus. Seek y-series or other fragments that retain the terminal group.

Selective derivatization provides useful orthogonal evidence. Published methods convert a free C-terminal carboxyl group into a methylamide, expanding the effective distinction from roughly 1 Da to about 14 Da, while an already amidated terminus remains unreactive. Reaction blanks, known acid and known amide controls are necessary because side-chain carboxyl groups and incomplete chemistry can complicate interpretation.

Method transfer is another weak point. A supplier may resolve acid and amide on a long shallow gradient, while the receiving lab uses a short screening method and sees one peak. Transfer the critical pair, not merely column dimensions. System suitability should include an acid/amide mixture near the reporting threshold, with resolution and retention acceptance criteria.

A defensible lot package contains:

• exact sequence with C-terminal –CONH2 stated explicitly;
• theoretical monoisotopic masses for amide and free-acid forms;
• raw high-resolution charge-state spectra and isotope fits;
• extracted-ion chromatograms for both structures;
• C-terminal MS/MS coverage or qualified orthogonal derivatization;
• numerical limit of detection and quantitation for free-acid impurity.

Avoid false assignments from nearby chemistry

Asn or Gln deamidation adds about 0.984 Da, while C-terminal amidation removes about 0.984 Da from the free-acid form. In a peptide containing susceptible amide side chains, several species can occupy a narrow mass window. Retention and site-localizing fragments matter more than a single deconvoluted number.

Sodium adducts and isotope-selection errors add further noise. Confirm the monoisotopic peak, charge, and isotope envelope before calculating neutral mass. If the reported difference changes when the deconvolution range changes, the assignment is not robust.

HPLC-UV area can quantify a resolved free-acid peak when response is comparable. MS ion-area percentages should not automatically be treated as mole percent; terminal charge can affect ionization. For a tight specification, use a characterized free-acid standard to establish retention and response.

The standard itself needs confirmation. Free-acid material prepared by hydrolysis may contain internal deamidation or other products, and an amidated reference may carry residual acid precursor. Qualify identity, purity, and content before using either to calculate response. A spiked resolution sample should reproduce the expected minor-peak recovery across analysts and days.

For short peptides, capillary electrophoresis can offer useful orthogonal selectivity because the terminal acid changes net charge with pH. It is not automatically quantitative and requires its own recovery and migration controls, but agreement between CE and LC-HRMS substantially strengthens a disputed assignment.

Supplier and stability review

Ask which resin and synthesis route produced the terminal amide. A mass screenshot labeled “pass” is weaker than route evidence plus orthogonal analysis. Confirm that HPLC and MS files have the same lot number and acquisition date. Generic reference spectra are common in weak COA packages.

Amidated peptides can still oxidize, deamidate internally, aggregate, or adsorb during storage. The terminal amide is usually not expected to hydrolyze rapidly under ordinary analytical handling, so a rising +0.984 Da peak may be side-chain deamidation rather than free-acid formation. Run time-course and site-localization experiments before declaring C-terminal hydrolysis.

Store lyophilized RUO material sealed, dry, and at the qualified frozen temperature. After reconstitution, control pH, temperature, and autosampler time. Use low-binding containers where recovery is concentration-dependent.

Peptides Archive can help laboratories audit terminal-amidation evidence and investigate one-dalton impurity disputes. This article is strictly Research Use Only and provides no human administration, dosing, diagnostic, or therapeutic guidance.

Primary records and verification routes

Use the primary paper, current regulator record, or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not evidence itself.